According to the 2010 Status Report on Prevention and Management of Postpartum Hemorrhage and Pre- Eclampsia/Eclampsia, misoprostol reportedly is on national EMLs in 61 percent of the 31 countries surveyed by USAID/MCHIP, although approved uses do not consistently include postpartum hemorrhage prevention or treatment. Sixty-seven percent of countries piloting distribution of misoprostol for postpartum hemorrhage prevention during home births (12) and 75 percent of countries scaling up misoprostol for home birth use (6) report having a national policy in place approving it for prevention of postpartum hemorrhage. 19 Information on misoprostol for off-label use, which is the practice of prescribing a.
